Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech 10-K packed with pharmacology jargon can feel like another clinical trial. Pasithea Therapeutics’ filings are especially intricate, detailing PAS-004 development costs, cash runway scenarios, and licensing clauses that change with every milestone. If you have ever searched, “How do I find Pasithea Therapeutics’ quarterly earnings report 10-Q filing?” or “Why did an executive exercise KTTAW warrants on a Form 4?”, you know the challenge.
Stock Titan’s AI solves this problem in seconds. Our platform streams every Pasithea Therapeutics SEC filing—10-K annual reports, 10-Q quarterlies, 8-K material event disclosures, and real-time Form 4 insider transactions—directly from EDGAR, then distills what matters. Need the R&D spend trend or details on that neurofibromatosis type 1 trial update? The AI summary points you there, while clickable highlights explain each accounting footnote in plain language. Investors asking, “What does Pasithea Therapeutics report about PAS-004 toxicology?” or “Where is Pasithea Therapeutics executive compensation proxy statement?” get immediate, searchable answers.
You’ll also find:
- Pasithea Therapeutics insider trading Form 4 transactions with warrant exercise timestamps
- Pasithea Therapeutics quarterly earnings report 10-Q filing cash-burn analysis
- Pasithea Therapeutics 8-K material events explained, from trial suspensions to licensing deals
- Pasithea Therapeutics annual report 10-K simplified, including going-concern and dilution risk notes
- Understanding Pasithea Therapeutics SEC documents with AI—no medical dictionary required
Whether you’re monitoring Pasithea Therapeutics executive stock transactions Form 4, comparing pipeline costs across quarters, or studying the proxy statement executive compensation tables, Stock Titan delivers the depth professionals need without the time sink.
Pasithea Therapeutics Corp. files a Form S-8 to register securities under its 2023 Stock Incentive Plan and incorporates by reference the Form S-8 filed on March 29, 2024. Stockholders approved an amendment to the 2023 Plan at the annual meeting on September 3, 2025. The filing references the company’s Annual Report for the year ended December 31, 2024 and Quarterly Reports for periods ended March 31, 2025 and June 30, 2025, and lists related exhibits and consents, including opinions from Lowenstein Sandler LLP and audit consent from CBIZ CPAs P.C.
Pasithea Therapeutics Corp. reported condensed interim results showing limited liquidity and continuing operating losses. The company held approximately $7.2 million of cash and reported working capital of about $6.9 million. Management discloses an accumulated deficit of approximately $56.9 million and recurring negative operating cash flows, including net cash used in operating activities of $6.9 million in the recent period. The filing states managements belief that, absent additional financing, there is substantial doubt about the company's ability to continue as a going concern for twelve months from the financial statement date. Capital raises during the period included a May 2025 public offering and related warrant exercises and aggregate gross proceeds of approximately $6.3 million from that offering, proceeds of approximately $4.5 million from a September 2024 private placement, and ATM sales during the six months ended June 30, 2025 generating gross proceeds of approximately $2.08 million. The company continues to depend on equity and/or debt financings to fund operations and development programs.
Pasithea Therapeutics reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclose beneficial ownership of 826,145 shares of common stock through Series C and Series D warrants, representing 9.9% of the outstanding class. The Warrants include a contractual limitation that prevents exercise to the extent such exercise would raise ownership above 9.99%. Heights Capital, as investment manager to CVI Investments, may be deemed to have shared voting and dispositive power over the reported position, while neither reporting person claims sole voting or dispositive power. The filing also references 7,443,577 shares outstanding (excluding shares underlying the warrants) as reported in the company's quarterly report.
Pasithea Therapeutics (Nasdaq:KTTA) filed an 8-K reporting receipt of a Nasdaq bid-price deficiency notice on 23-Jun-2025. The company’s shares traded below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). Pasithea has 180 days—until 22-Dec-2025—to regain compliance by posting a closing bid of at least $1.00 for 10 straight sessions. A second 180-day extension is possible if other listing standards are met and the firm commits to a remedy such as a reverse split. There is no immediate delisting; business operations and SEC reporting remain unaffected. Management is monitoring share price and evaluating options to restore compliance.
FAQ
What is the current stock price of Pasithea Therapeutics (KTTAW)?
